Last reviewed · How we verify
Pirarubicin Hydrochloride for Injection
Pirarubicin Hydrochloride for Injection is an anthracycline antibiotic that intercalates DNA strands, thereby inhibiting the synthesis of nucleic acids and inducing apoptosis in cancer cells.
Pirarubicin Hydrochloride for Injection is an anthracycline antibiotic that intercalates DNA strands, thereby inhibiting the synthesis of nucleic acids and inducing apoptosis in cancer cells. Used for Advanced breast cancer.
At a glance
| Generic name | Pirarubicin Hydrochloride for Injection |
|---|---|
| Sponsor | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| Drug class | Anthracycline antibiotic |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Pirarubicin Hydrochloride for Injection works by intercalating DNA strands, which prevents the replication of cancer cells. This leads to the induction of apoptosis, or programmed cell death, in cancer cells. The anthracycline antibiotic class of drugs, to which Pirarubicin Hydrochloride for Injection belongs, has been used for decades to treat various types of cancer.
Approved indications
- Advanced breast cancer
Common side effects
- Myelosuppression
- Cardiotoxicity
- Nausea and vomiting
- Diarrhea
- Fatigue
Key clinical trials
- A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC (PHASE3)
- Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer (PHASE2)
- Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma (PHASE2)
- Endostar Combined With Chemotherapy for Stage Ⅳ Soft Tissue Sarcoma (PHASE2)
- Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy (PHASE2)
- Combine TACE and RFA Versus TACE Alone for HCC With PVTT (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: